Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Gilead Sciences (GILD) reported first quarter earnings that topped analyst estimates, but its revenue in the quarter fell ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Gilead’s HIV product sales, which make up the bulk of its revenue, increased 6% YoY to $4.6 billion, but fell 16% ...

Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.

Reports Q1 reveue $6.7B, consensus $6.81B. “Gilead (GILD) had a strong start to the year driven by excellent commercial and clinical execution ...

Gilead Sciences Inc . (NASDAQ: GILD) reported first quarter earnings that beat expectations, but shares fell 2.9% in ...

FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.